Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12809399 | 0.95 | HDAC4 (0.58) | HDAC1HDAC8HDAC4CNR2NLRP3 | |
| SCHEMBL10094801 | 0.92 | HDAC1 (0.75) | HDAC1HDAC8HDAC4CNR2NLRP3 | |
| SCHEMBL12993371 | 0.83 | ESRRB (0.58) | HDAC8NLRP3EPHX2ALDH1A1KCNH2 | |
| SCHEMBL714137 | 0.83 | HDAC1 (0.63) | HDAC1HDAC8CNR2NLRP3MAPK8 | |
| SCHEMBL4441717 | 0.82 | HDAC1 (0.54) | HDAC1HDAC8UTS2R | |
| SCHEMBL29995593 | 0.81 | HDAC1 (0.56) | HDAC1HDAC8CNR2NLRP3MAPK8 | |
| Hydrochloric Acid SCHEMBL6208799 | 0.80 | TACR1 (0.52) | HDAC1HDAC8HDAC4KDM4ECYP2D6 | |
| SCHEMBL6850939 | 0.80 | MEN1 (0.67) | HDAC1HDAC8HDAC4MAPK8SIGMAR1 | |
| SCHEMBL14476867 | 0.79 | HDAC1 (0.58) | HDAC1HDAC8CNR2NLRP3MAPK8 | |
| SCHEMBL265118 | 0.79 | PIK3CA (0.53) | HDAC1HDAC8CNR2NLRP3PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3016950-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9663529-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663529-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | HDAC1 371/4885HDAC8 445/4885HDAC4 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.